201 related articles for article (PubMed ID: 16411132)
21. Expression of p53 in adenocarcinoma of the gallbladder and bile ducts.
Washington K; Gottfried MR
Liver; 1996 Apr; 16(2):99-104. PubMed ID: 8740842
[TBL] [Abstract][Full Text] [Related]
22. The significance of galectin-3 immunohistochemistry, clinical characteristics and liver imaging in differentiating intrahepatic cholangiocarcinoma from adenocarcinoma liver metastasis.
Dechaphunkul A; Kanngurn S; Dechsukhum C; Tanutit P; Khow-Ean U; Sunpaweravong P
J Med Assoc Thai; 2010 May; 93(5):523-8. PubMed ID: 20524437
[TBL] [Abstract][Full Text] [Related]
23. Case report: biliary cystadenoma with mucin-secretion mimicking a simple hepatic cyst.
Matsumoto S; Miyake H; Mori H
Clin Radiol; 1997 Apr; 52(4):316-8. PubMed ID: 9112956
[No Abstract] [Full Text] [Related]
24. Tubulin β-III: a novel immunohistochemical marker for intrahepatic peripheral cholangiocarcinoma.
Zen Y; Britton D; Mitra V; Pike I; Sarker D; Itoh T; Heaton N; Quaglia A
Histopathology; 2014 Dec; 65(6):784-92. PubMed ID: 25039376
[TBL] [Abstract][Full Text] [Related]
25. Multiloculated cystic liver lesions: radiologic-pathologic differential diagnosis.
Singh Y; Winick AB; Tabbara SO
Radiographics; 1997; 17(1):219-24. PubMed ID: 9017811
[No Abstract] [Full Text] [Related]
26. Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma.
Zimmerman RL; Fogt F; Burke M; Murakata LA
Oncol Rep; 2002; 9(4):689-92. PubMed ID: 12066193
[TBL] [Abstract][Full Text] [Related]
27. Alpha-fetoprotein-producing clear cell carcinoma of the extrahepatic bile ducts.
Miyazawa M; Torii T; Toshimitsu Y; Kamizasa N; Suzuki T; Shinozuka N; Ishizawa K; Koyama I
J Clin Gastroenterol; 2006 Jul; 40(6):555-7. PubMed ID: 16825940
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical analysis of biliary tract lesions.
Tan G; Yilmaz A; De Young BR; Behling C; Lehman A; Frankel WL
Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):193-7. PubMed ID: 15551730
[TBL] [Abstract][Full Text] [Related]
29. INTRAHEPATIC BILIARY PROLIFERATIONS: HISTOPATHOLOGY AND POTENTIAL IMMUNOHISTOCHEMICAL MARKERS.
Hirayama AB; Mello ES; Alves VAF
Arq Gastroenterol; 2023; 60(3):393-403. PubMed ID: 37792770
[TBL] [Abstract][Full Text] [Related]
30. Claudin-7-positive synchronous spontaneous intrahepatic cholangiocarcinoma, adenocarcinoma and adenomas of the gallbladder in a Bearded dragon (Pogona vitticeps).
Jakab C; Rusvai M; Szabó Z; Gálfi P; Marosán M; Kulka J; Gál J
Acta Vet Hung; 2011 Mar; 59(1):99-112. PubMed ID: 21354945
[TBL] [Abstract][Full Text] [Related]
31. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.
Sasaki M; Matsubara T; Kakuda Y; Sato Y; Nakanuma Y
Am J Surg Pathol; 2014 Mar; 38(3):364-9. PubMed ID: 24487593
[TBL] [Abstract][Full Text] [Related]
32. Bile duct adenoma and von Meyenburg complex-like duct arising in hepatitis and cirrhosis: pathogenesis and histological characteristics.
Aishima S; Tanaka Y; Kubo Y; Shirabe K; Maehara Y; Oda Y
Pathol Int; 2014 Nov; 64(11):551-9. PubMed ID: 25329860
[TBL] [Abstract][Full Text] [Related]
33. Role of CD15 expression in dysplastic and neoplastic tissue of the bile duct - a potential novel tool for differential diagnosis of indeterminate biliary stricture.
Walter D; Herrmann E; Winkelmann R; Albert JG; Liese J; Schnitzbauer A; Zeuzem S; Hansmann ML; Peveling-Oberhag J; Hartmann S
Histopathology; 2016 Dec; 69(6):962-970. PubMed ID: 27442966
[TBL] [Abstract][Full Text] [Related]
34. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver.
de Boer CJ; van Krieken JH; Janssen-van Rhijn CM; Litvinov SV
J Pathol; 1999 Jun; 188(2):201-6. PubMed ID: 10398165
[TBL] [Abstract][Full Text] [Related]
35. Expression of blood group-related antigens in cholangiocarcinoma in relation to non-neoplastic bile ducts.
Minato H; Nakanuma Y; Terada T
Histopathology; 1996 May; 28(5):411-9. PubMed ID: 8735716
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical detection of bcl-2 protein in normal and pathological human liver.
Charlotte F; L'Herminé A; Martin N; Geleyn Y; Nollet M; Gaulard P; Zafrani ES
Am J Pathol; 1994 Mar; 144(3):460-5. PubMed ID: 8129031
[TBL] [Abstract][Full Text] [Related]
37. Different expression of glucose transporters in the progression of intrahepatic cholangiocarcinoma.
Kubo Y; Aishima S; Tanaka Y; Shindo K; Mizuuchi Y; Abe K; Shirabe K; Maehara Y; Honda H; Oda Y
Hum Pathol; 2014 Aug; 45(8):1610-7. PubMed ID: 24824030
[TBL] [Abstract][Full Text] [Related]
38. Identification of novel biomarker candidates for the immunohistochemical diagnosis of cholangiocellular carcinoma.
Padden J; Megger DA; Bracht T; Reis H; Ahrens M; Kohl M; Eisenacher M; Schlaak JF; Canbay AE; Weber F; Hoffmann AC; Kuhlmann K; Meyer HE; Baba HA; Sitek B
Mol Cell Proteomics; 2014 Oct; 13(10):2661-72. PubMed ID: 25034945
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic study of mixed adenoneuroendocrine carcinomas of hepatobiliary organs.
Harada K; Sato Y; Ikeda H; Maylee H; Igarashi S; Okamura A; Masuda S; Nakanuma Y
Virchows Arch; 2012 Mar; 460(3):281-9. PubMed ID: 22358181
[TBL] [Abstract][Full Text] [Related]
40. Surveillance in cholangiocellular carcinoma.
Wirth TC; Vogel A
Best Pract Res Clin Gastroenterol; 2016 Dec; 30(6):987-999. PubMed ID: 27938792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
